Indexed In
- Open J Gate
- Genamics JournalSeek
- CiteFactor
- Cosmos IF
- Scimago
- Ulrich's Periodicals Directory
- Electronic Journals Library
- RefSeek
- Hamdard University
- EBSCO A-Z
- Directory of Abstract Indexing for Journals
- OCLC- WorldCat
- Proquest Summons
- Scholarsteer
- ROAD
- Virtual Library of Biology (vifabio)
- Publons
- Geneva Foundation for Medical Education and Research
- Google Scholar
Useful Links
Share This Page
Journal Flyer
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
Mohamed Abdelmooti Mohamed Samra
Department of Hematology, Nasser Cancer Institute, Cairo, Egypt
Publications
-
Research Article
Prognostic Significance of Early Molecular Response in Patients Diagnosed with Chronic Myeloid Leukemia in Chronic Phase Treated with Nilotinib: A First-Line Therapy
Author(s): Mohammad Abdallah Shazly*, Mohamed Osman Azzazi, Mohamed Abdelmooti Mohamed Samra and Ahmed Youssri Elsaed
Background: Chronic Myeloid Leukemia (CML) is one of malignant hematologic disorders arises from hematopoietic stem cells. BCR-ABL transcript levels on the international scale at 3 and 6 months are defined as indicators of the early efficacy of first line TKI treatment. Aim To investigate the impact of Early Molecular Response (EMR; BCR-ABL ≤ 10% on the International scale at 3 or 6 months) on outcome of the newly diagnosed CML in chronic phase treated with Nilotinib. Patients and Methods: The study was enrolled from 2018 to 2020 at Nasser Institute for Research and Treatment. This is a prospective cohort study done on 94 newly diagnosed CML cases in Chronic Phase. Results: A statistically significant difference was detected between patients not achieved EMR with peripheral blasts ≥ 5%, whe.. View more»